WILMINGTON, Del., November 14, 2024--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it will present at Citi’s ...

Janney Montgomery Scott LLC reduced its stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 9.6% in the third ...

WILMINGTON, Del., November 07, 2024--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that it granted restricted stock ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. Find out ...

Capital Performance Advisors LLP bought a new position in Incyte Co. (NASDAQ:INCY – Free Report) in the third quarter, ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

Incyte Corp (INCY) reports a 24% revenue increase, driven by Jakafi and Opzelura, while navigating regulatory challenges and ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Incyte delivered robust third-quarter revenue growth, surpassing expectations, despite increased operational costs.